Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults

  1. Barbour, T.
  2. Scully, M.
  3. Ariceta, G.
  4. Cataland, S.
  5. Garlo, K.
  6. Heyne, N.
  7. Luque, Y.
  8. Menne, J.
  9. Miyakawa, Y.
  10. Yoon, S.-S.
  11. Kavanagh, D.
  12. Babu, S.
  13. Broeders, N.
  14. Lietar, N.
  15. Brown, F.
  16. Campbell, P.
  17. Campistol, J.M.
  18. Chowdhury, P.
  19. Kasimatis, T.
  20. Cirami, L.
  21. Caroti, L.
  22. Antognoli, G.
  23. Delmas, Y.
  24. Dobronravov, V.
  25. Gaeckler, A.
  26. Garrouste, C.
  27. Greenwood, G.
  28. Griffin, S.
  29. Huang, C.-C.
  30. Chen, I.-R.
  31. Huang, S.
  32. Kim, J.S.
  33. La Manna, G.
  34. Le Quintrec, M.
  35. Jeantet, G.
  36. Fumie, I.
  37. Rondeau, E.
  38. Haller, H.
  39. Morelle, J.
  40. Goffin, E.
  41. Muhlfeld, A.
  42. Nagaraj, S.
  43. Arepally, G.
  44. Oh, D.
  45. Okumi, M.
  46. Terente, M.P.
  47. Provot, F.
  48. Schönermarck, U.
  49. Fischereder, M.
  50. Terrada, N.R.
  51. Seitz-Polski, B.
  52. Favre, G.
  53. Boyer-Suavet, S.
  54. Vinogradova, M.
  55. Kirsanova, T.
  56. Wong, E.K.S.
  57. Show all authors +
Journal:
Kidney International Reports

ISSN: 2468-0249

Year of publication: 2021

Volume: 6

Issue: 6

Pages: 1603-1613

Type: Article

DOI: 10.1016/J.EKIR.2021.03.884 GOOGLE SCHOLAR lock_openOpen access editor
Data source: Scopus